Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Blood
|
May 30, 2014
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
Miguel Hie, Julie Gay, Lionel Galicier, et al.
British Journal of Haematology
|
May 29, 2024
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
Aurore Perrot, Murielle Roussel, Valerie Lauwers-Cances, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia
Eileen Boyle, Salomon Manier, Julie Lejeune, et al.
British Journal of Haematology
|
January 6, 2025
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Cyrille Touzeau, Xavier Leleu, Mourad Tiab, et al.
The New England Journal of Medicine
|
June 3, 2025
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma
Aurore Perrot, Jérôme Lambert, Cyrille Hulin, et al.
Nature Communications
|
August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
Bulletin Du Cancer
|
September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]
Roch Houot, Claire Calmettes, Sophie Park, et al.
Eclinicalmedicine
|
January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Blood
|
January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
Aurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Nature Medicine
|
June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Blood
|
May 30, 2014
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
Miguel Hie, Julie Gay, Lionel Galicier, et al.
British Journal of Haematology
|
May 29, 2024
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03
Aurore Perrot, Murielle Roussel, Valerie Lauwers-Cances, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia
Eileen Boyle, Salomon Manier, Julie Lejeune, et al.
British Journal of Haematology
|
January 6, 2025
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Cyrille Touzeau, Xavier Leleu, Mourad Tiab, et al.
The New England Journal of Medicine
|
June 3, 2025
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma
Aurore Perrot, Jérôme Lambert, Cyrille Hulin, et al.
Nature Communications
|
August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
Bulletin Du Cancer
|
September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]
Roch Houot, Claire Calmettes, Sophie Park, et al.
Eclinicalmedicine
|
January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Blood
|
January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
Aurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Nature Medicine
|
June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Page
of 2